SS
MTNB icon

Steve Schonfeld’s Matinas BioPharma MTNB Stock Holding History

Steve Schonfeld’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-251
Closed -$13K – 2171
2021
Q1 		$13K Buy
+251
New +$16.8K ﹤0.01% 1745
2019
Q3 		– Sell
-1,068
Closed -$46K – 1159
2019
Q2 		$46K Sell
1,068
-898
-46% -$43.2K ﹤0.01% 943
2019
Q1 		$107K Buy
+1,966
New +$106K ﹤0.01% 989

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Steve Schonfeld's MTNB Position: Q2 2021 in Review

Steve Schonfeld sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 251 shares — an estimated $13K sold.

Steve Schonfeld first reported a position in MTNB in Q1 2019 and held it in 3 quarters. The position peaked at $107K in Q1 2019. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • Steve Schonfeld reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • Steve Schonfeld sold 251 Matinas BioPharma shares in Q2 2021, an estimated $13K.
  • Steve Schonfeld first reported a position in Matinas BioPharma in Q1 2019 and held it in 3 quarters.
  • Steve Schonfeld's Matinas BioPharma position peaked at $107K in Q1 2019.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.